English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Ovarian cancer is a low incidence cancer with high mortality rate [1]. The asymptomatic na‐ ture of this cancer and the late stage diagnosis of most tumors are the reasons for ineffective surgery and chemotherapy [2]. In this sense, intensive research aim at increasing overall pa‐ tient survival and quality of life by providing biomarkers for 1) early detection and 2) pre‐ diction of chemotherapy response and/or suggestion of alternative strategies. CA-125 is a glycoprotein that is usually expressed in a variety of epithelial cells and its serum level rise up in advance ovarian cancer [3]. However, its use as an early detection marker or as a tool to screen the general population has not been approved so far [4,5]. CA-125 level is helpful in treatment-decision making but do not retain the capacity to improve overall survival and quality of life [6,7]. Clearly, there is still great need for biomarkers or combination of bio‐ markers that could positively identify early ovarian cancer lesions with great certainty or in‐ crease patients’ survival.

The Merit of Alternative Messenger RNA Splicing as a New Mine for the Next Generation Ovarian Cancer Biomarkers